US · Healthcare · Biotechnology
EPS came in at -0.49 against a street estimate of -0.39 — a miss of 25.6%.
Analysts rate Structure Therapeutics Inc. American Depositary Shares a strong buy (14 buy, 0 hold, 0 sell out of 14) with an average price target of $105.78.
| Fund | Stake |
|---|---|
| FMR Inc | 11.78% |
| Wellington Management Company LLP | 10.35% |
| venBio Select Advisor LLC | 9.19% |
| HHG PLC | 7.51% |
| Deep Track Capital, LP | 6.65% |
| Bvf Inc | 4.85% |
| Morgan Stanley - Brokerage Accounts | 3.23% |
| T. Rowe Price Associates, Inc. | 2.81% |
| Document | Date |
|---|---|
| Reg FD disclosure · Q3 2026 STRUCTURE THERAPEUTICS INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Company reported positive Phase 1/2a SAD (single ascending dose) clinical trial re | 2026-09-08 |
| Quarterly report · Q2 2026 STRUCTURE THERAPEUTICS INC. – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash and short-term investments: $1,342.7 million as of June 30, 2026 (down fr | 2026-08-06 |
| Results announced · Q3 2026 STRUCTURE THERAPEUTICS INC. – Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash, cash equivalents and short-term investments: $1.3 billion a | 2026-08-06 |
| Shareholder vote results · Q2 2026 STRUCTURE THERAPEUTICS INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Record Date: April 20, 2026 • Outstanding Shares: 213,213,565 ordinary shares (ent | 2026-06-18 |
| Quarterly report · Q1 2026 STRUCTURE THERAPEUTICS INC. — Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash and liquid assets: $1.46 billion in total shareholders' equity as of Marc | 2026-05-07 |
| Results announced · Q2 2026 STRUCTURE THERAPEUTICS INC. – Q1 2026 SUMMARY HEADLINE NUMBERS • Cash, cash equivalents and short-term investments: $1.5 billion as of March 31, 202 | 2026-05-07 |
| Proxy statement · Q2 2026 STRUCTURE THERAPEUTICS INC. — 2026 PROXY STATEMENT SUMMARY --- WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Election of Three Class III Directors | 2026-04-23 |
| Annual report FY2025 STRUCTURE THERAPEUTICS INC. – FORM 10-K SUMMARY Fiscal Year Ended December 31, 2025 --- HEADLINE NUMBERS • Public float (non-affiliate market value | 2026-02-26 |
Readable in the app.
| Announcement | Date |
|---|---|
| Patent license agreement with Genentech for GLP-1 receptor agonist compound Structure Therapeutics' subsidiary Gasherbrum signed a licensing agreement with Genentech/Roche on December 30, 2025. Under the deal, Gasherbrum granted Genentech a non-exclusive license to | 2026-01-05 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Structure Therapeutics Inc. American Depositary Shares — free to start.
Google PlayApp StoreData updated 2026-09-18.